Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2021 - 2025)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Amortization of Deferred Charges came in at $103000.0 in Q2 2025, down 16.26% year-on-year from $123000.0 in Q2 2024, and little changed quarter-over-quarter from $103000.0 in Q1 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2021 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $103000.0 for Q2 2025.
- On a quarterly basis, Amortization of Deferred Charges fell 16.26% year-over-year to $103000.0 in Q2 2025; TTM through Jun 2025 was $337000.0, a 26.1% decrease from a year earlier, with the FY2024 full-year figure at $377000.0, up 18.93% from the prior year.
- Amortization of Deferred Charges steadied at $103000.0 in Q2 2025 per VRDN's latest filing, from $103000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $128000.0 in Q4 2022 and bottomed at $49000.0 in Q3 2022.
- The 5-year median for Amortization of Deferred Charges is $87000.0 (2021), against an average of $86785.7.
- Biggest YoY gain for Amortization of Deferred Charges was 132.08% in 2024; the steepest drop was 52.03% in 2024.
- Year by year, Amortization of Deferred Charges stood at $87000.0 in 2021, then surged by 47.13% to $128000.0 in 2022, then slipped by 3.91% to $123000.0 in 2023, then sank by 52.03% to $59000.0 in 2024, then jumped by 74.58% to $103000.0 in 2025.
- Per Business Quant, the three latest VRDN Amortization of Deferred Charges figures stand at $103000.0 (Q2 2025), $103000.0 (Q1 2025), and $59000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 655.26 Mn | 655.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Dec 31, 2024 | 59,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Mar 31, 2024 | 123,000.00 |
| Dec 31, 2023 | 123,000.00 |
| Dec 31, 2023 | 123,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 53,000.00 |
| Mar 31, 2023 | 53,000.00 |